


IRAK4-IN-17

Cat. No.:	HY-150594
CAS No.:	2183503-33-3
Molecular Formula:	C ₁₇ H ₂₀ F ₂ N ₈ O
Molecular Weight:	390.39
Target:	IRAK; NF-κB
Pathway:	Immunology/Inflammation; NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC ₅₀ of 1.3 nM ^[1] . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research ^[1] .																
IC₅₀ & Target	IRAK4 1.3 nM (IC ₅₀)																
In Vitro	<p>IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation^[1]. IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>OCI-LY10, TMD8, Ramos and HT cells</td> </tr> <tr> <td>Concentration:</td> <td>0.7-40.1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC₅₀=0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC₅₀=11.4 μM and 40.1 μM, respectively).</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>OCI-LY10 and TMD8 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.3, 1, 3 and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>2 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.</td> </tr> </table>	Cell Line:	OCI-LY10, TMD8, Ramos and HT cells	Concentration:	0.7-40.1 μM	Incubation Time:	72 hours	Result:	Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC ₅₀ =0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC ₅₀ =11.4 μM and 40.1 μM, respectively).	Cell Line:	OCI-LY10 and TMD8 cells	Concentration:	0.3, 1, 3 and 10 μM	Incubation Time:	2 hours	Result:	Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.
Cell Line:	OCI-LY10, TMD8, Ramos and HT cells																
Concentration:	0.7-40.1 μM																
Incubation Time:	72 hours																
Result:	Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC ₅₀ =0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC ₅₀ =11.4 μM and 40.1 μM, respectively).																
Cell Line:	OCI-LY10 and TMD8 cells																
Concentration:	0.3, 1, 3 and 10 μM																
Incubation Time:	2 hours																
Result:	Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.																

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA